Sorry, you need to enable JavaScript to visit this website.
  1. Home
  2. Our Science
  3. Clinical Trials
  4. Plain Language Study Results Summaries

Plain Language Study Results Summaries

What Are Plain Language Study Results Summaries?

Plain Language Study Results Summaries are descriptions in everyday language of the design and results of clinical studies. These summaries, also called plain language summaries, simple summaries, and trial results summaries, are intended to make clinical results understandable and accessible to patients, healthcare providers, caregivers, researchers, and a general audience.

Please use the search function below to find Plain Language Study Results Summaries for Pfizer-sponsored global clinical trials.

Filter Results

Refine your search results by using the dropdown filters below. Click “reset” to return to the full list of available studies.

Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis
Category & Conditions: Skin Diseases and Conditions
Study Phase : 2
Medicine: PF-06700841
Language: English
ViewDownloadPrint
Study to Assess the Efficacy and Safety of PF-06651600 in Subjects with Rheumatoid Arthritis with an Inadequate Response to Methotrexate
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 2
Medicine: PF-06651600
Language: English
ViewDownloadPrint
A Placebo Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-06651600 in Adult and Adolescent Alopecia Areata (AA) Subjects
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 2/3
Medicine: PF-06651600
Language: English
ViewDownloadPrint
Study to Evaluate the Efficacy and Safety of PF-06651600 and PF-06700841 to Treat Moderate to Severe Alopecia Areata in Adults
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 2
Medicine: PF-06651600, PF-06700841
Language: English
ViewDownloadPrint
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Category & Conditions: Cancer
Study Phase : 1/2
Medicine: ARRY-382 (PF-07265804)
Language: English
ViewDownloadPrint
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Boys with Duchenne Muscular Dystrophy
Category & Conditions: Rare Diseases
Study Phase : 2
Medicine: Domagrozumab (PF-06252616)
Language: English
ViewDownloadPrint
An Open-label Extension Study To Evaluate Safety Of PF-06252616 in Boys With Duchenne Muscular Dystrophy
Category & Conditions: Rare Diseases
Study Phase : 2
Medicine: Domagrozumab (PF-06252616)
Language: English
ViewDownloadPrint
Efficacy, Safety, and Tolerability of PF-06649751 in Parkinson’s Disease Patients at Early Stage of the Disease
Category & Conditions: Neurological Diseases and Conditions
Study Phase : 2
Medicine: PF-06649751
Language: English
ViewDownloadPrint
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Category & Conditions: Infections and Infectious Diseases
Study Phase : 3
Medicine: Anidulafungin (PF-03910960)
Language: English
ViewDownloadPrint
Study of the immunogenicity, safety, and tolerability of PF-05212366 in healthy toddlers aged 12 to less than 18 Months and 18 to less than 24 months
Category & Conditions: Vaccine-related Conditions
Study Phase : 2
Medicine: PF-05212366 (Bivalent rLP2086)
Language: English
ViewDownloadPrint
Tutkimus, jossa selvitetään B ryhmän meningokokin aiheuttaman aivokalvontulehduksen ehkäisyyn kehitetyn rokotteen immunogeenisuutta, turvallisuutta ja siedettävyyttä 1–1,5-vuotiailla ja 1,5–2-vuotiailla terveillä lapsilla
Category & Conditions: Vaccine-related Conditions
Study Phase : 2
Medicine: PF-05212366 (Bivalent rLP2086)
Language: Finnish
ViewDownloadPrint
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
Category & Conditions: Vaccine-related Conditions
Study Phase : 3
Medicine: PF-05212366 (Bivalent rLP2086)
Language: English
ViewDownloadPrint